Phase IV study evaluated Deep TMS for major depression in community settings. Data were aggregated from 1753 patients at 21 sites, who received Deep TMS (high frequency or iTBS) using the H1 coil. Outcome measures varied across subjects and included clinician-based scales (HDRS-21) and self-assessment questionnaires (PHQ-9, BDI-II). 1351 patients were included in the analysis, 202 received iTBS. For participants with data from at least 1 scale, 30 sessions of Deep TMS led to 81.6% response and 65.3% remission rate. 20 sessions led to 73.6% response and 58.1% remission rate. iTBS led to 72.4% response and 69.2% remission. Remission rates were highest when assessed with HDRS (72%). In 84% of responders and 80% of remitters, response and remission was sustained in the subsequent assessment. Median number of sessions (days) for onset of sustained response was 16 (21 days) and for sustained remission 17 (23 days). Higher stimulation intensity was associated with superior clinical outcomes. This study shows that beyond its proven efficacy in RCTs, Deep TMS with the H1 coil is effective for treating depression under naturalistic conditions, and the onset of improvement is usually within 20 sessions. However, initial non-responders and non-remitters benefit from extended treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.psychres.2023.115179 | DOI Listing |
AIMS Neurosci
October 2024
Department of Surgical, Medical, Molecular & Critical Area Pathology, University of Pisa, via Savi, 10, 56126, Pisa, Italy.
The purpose of the present study was to investigate the effects of neuromodulation techniques, including transcranial direct current stimulation, transcranial magnetic stimulation, and deep brain stimulation, on the treatments of nicotine dependence. Specifically, our objective was to assess the existing evidence by conducting an umbrella review of systematic reviews. The quality of the included studies was evaluated using the standardized tools designed to evaluate systematic reviews.
View Article and Find Full Text PDFPharmaceuticals (Basel)
November 2024
The Research Institute, The McGill University Health Center, Montreal, QC H4A 3J1, Canada.
Glioblastoma multiforme is an aggressive malignancy with a dismal 5-year survival rate of 5-10%. Current therapeutic options are limited, due in part to drug exclusion by the blood-brain barrier (BBB). We have previously shown that high-amplitude repetitive transcranial magnetic stimulation (rTMS) in rats allowed the delivery across the BBB of an IGF signaling inhibitor-IGF-Trap.
View Article and Find Full Text PDFBehav Sci (Basel)
December 2024
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazza Aldo Moro, 100165 Rome, Italy.
Bipolar disorder is a debilitating psychiatric condition characterized by recurrent episodes of mania and depression, affecting millions worldwide. While pharmacotherapy remains the cornerstone of treatment, a significant proportion of patients exhibit inadequate response or intolerable side effects to conventional medications. In recent years, neuromodulation techniques have emerged as promising adjunctive or alternative treatments for bipolar disorder.
View Article and Find Full Text PDFSci Rep
January 2025
School of Computer Science and Technology, Yibin University, Yibin, 644000, China.
Personalized tourism has recently become an increasingly popular mode of travel. Effective personalized route recommendations must consider numerous complex factors, including the vast historical trajectory of tourism, individual traveler preferences, and real-time environmental conditions. However, the large temporal and spatial spans of trajectory data pose significant challenges to achieving high relevance and accuracy in personalized route recommendation systems.
View Article and Find Full Text PDFExpert Rev Neurother
January 2025
Harquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
Introduction: Post-traumatic stress disorder (PTSD) can have debilitating effects on quality of life, and conventional treatments show mixed results. Neuromodulation is emerging as a promising approach for treating PTSD. This review examines current neuromodulatory treatments for PTSD, and highlights methodologies, clinical outcomes, and gaps in the literature to help guide future research.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!